Km. Shannon et al., RECOMBINANT-HUMAN-ERYTHROPOIETIN STIMULATES ERYTHROPOIESIS AND REDUCES ERYTHROCYTE TRANSFUSIONS IN VERY-LOW-BIRTH-WEIGHT PRETERM INFANTS, Pediatrics, 95(1), 1995, pp. 1-8
Design and methods. We hypothesized that treatment with recombinant hu
man erythropoietin (r-HuEPO) would stimulate erythropoiesis and would
thereby reduce the need for erythrocyte transfusions in preterm infant
s. We treated 157 preterm infants born at 26.9 +/- 1.6 weeks of gestat
ion who weighed 924 +/- 183 g at birth with either subcutaneous r-HuEP
O (100 U/kg/d, 5 days per week) or placebo for 6 weeks in a randomized
, double-blind, controlled clinical trial. All patients received oral
iron and were managed according to uniform conservative transfusion gu
idelines. Results. Treatment with r-HuEPO was associated with fewer er
ythrocyte transfusions (1.1 +/- 1.5 per infant in the r-HuEPO group ve
rsus 1.6 +/- 1.7 per infant in the placebo group; P = .046) and with a
reduction in the volume of packed erythrocytes transfused (16.5 +/- 2
3.0 mL versus 23.9 +/- 25.7 mL per infant; P = .023). Overall, 43% of
the infants in the r-HuEPO group and 31% of placebo-treated infants we
re transfusion-free during the study (P = .18). The volume of blood re
moved for laboratory tests and the need for respiratory support at the
start of treatment had major effects on transfusion requirements inde
pendent of r-HuEPO. Reticulocyte counts were higher during treatment i
n the r-HuEPO group (P = .0001), and r-HuEPO-treated infants had highe
r hematocrit values at the end of the study (32% versus 27.3% in the p
lacebo group; P = .0001). We found no differences in the incidence of
major complications of prematurity between the treatment groups. Concl
usion. We conclude that treatment with r-HuEPO at a weekly dose of 500
U/kg stimulates erythropoiesis, moderates the course of anemia, is as
sociated with a reduction in erythrocyte transfusions, and appears saf
e in very low birth weight preterm infants who are receiving iron supp
lements. Conservative transfusion criteria, minimization of phlebotomy
losses, and treatment with r-HuEPO are complementary strategies to re
duce erythrocyte transfusions in these infants.